Neurogene Inc.

Ownership Transactions Reported by 22 Insiders

Symbol
NGNE on Nasdaq
Industry
Pharmaceutical Preparations
Location
535 W 24 Th Street, 5 Th Floor, New York, New York

There are no Buy or Sell transactions made by insiders since 8/26/2023

Neurogene Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Rachel McMinn Chief Executive Officer, Director $866K Mar 13, 2024
Baker Bros. Advisors Lp Director, Former 10% Owner $287K Dec 18, 2023
Christine Mikail Cvijic President and CFO $36.6K Mar 13, 2024
Priti Patel Former Chief Medical Officer $25.9K Mar 31, 2023
Sean Smith Interim CFO, Prin Acct Off $15K Aug 10, 2023
Stuart Cobb Chief Scientific Officer $14.1K Mar 13, 2024
Jonathan G. Drachman President and CEO, Director Aug 2, 2022
Robert Ho Chief Financial Officer Feb 1, 2022
Holly Vance General Counsel Aug 3, 2021
Lewis T. Williams Director May 11, 2021
Carl Walkey Senior Vice President Aug 2, 2022
Erin M. Lavelle Director May 11, 2021
Donna Cochener General Counsel, SVP Legal Aug 2, 2022
Erin Lavelle Director Jun 8, 2023
Martin Babler Director Jun 8, 2023
Todd E. Simpson Director Jun 8, 2023
Robert Keith Woods Director Jun 14, 2024
Julie Jordan Chief Medical Officer Jan 16, 2024
Rohan Palekar Director Jun 14, 2024
Sarah B. Noonberg Director Jun 14, 2024
Robert Baffi Director Jun 14, 2024
Cory S. Freedland Director Jun 14, 2024

Recent Insider Transactions by Companies or Individuals for Neurogene Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.